The Therapeutic Effect of Lactobacillus reuteri in Acute Diarrhea in Infants and Toddlers

영유아의 급성 설사에서 Lactobacillus reuteri의 치료 효과

  • Eom, Tae-Hun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Oh, Eun-Young (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Young-Hoon (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Lee, Hyun-Seung (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Jang, Pil Sang (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Dong-un (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Jin-Tack (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Lee, Byung-Churl (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 엄태훈 (가톨릭대학교 의과대학 소아과학교실) ;
  • 오은영 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김영훈 (가톨릭대학교 의과대학 소아과학교실) ;
  • 이현승 (가톨릭대학교 의과대학 소아과학교실) ;
  • 장필상 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김동언 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김진택 (가톨릭대학교 의과대학 소아과학교실) ;
  • 이병철 (가톨릭대학교 의과대학 소아과학교실)
  • Received : 2005.04.04
  • Accepted : 2005.06.21
  • Published : 2005.09.15

Abstract

Purpose : Certain strains of lactobacilli are known to accelerate recovery from acute diarrhea. Lactobacillus reuteri is isolated from human breast milk and a commonly occurring Lactobacillus species with therapeutic potential in acute diarrhea. The purpose of the present study was to investigate the therapeutic effect of L. reuteri in acute diarrhea in young children. Methods : Fifty patients between 6 and 36 months of age hospitalized with acute diarrhea (rotavirus in 40 percent) were randomized into two groups to receive either $10^8$ colony-forming units of L. reuteri or a matching placebo, twice a day for their length of hospitalization, or for up to 5 days. Antidiarrheal drugs were not prescribed to either group. The clinical outcome of diarrhea was evaluated. Results : The mean duration of watery diarrhea after initiation of treatment was 2.3 days for the L. leuteri group(n=25) vs. 2.9 days for the placebo group(n=25)(P=0.072). By the second day of treatment, watery diarrhea persisted in 64 percent of patients receiving L. reuteri, compared to 84 percent of those receiving placebo(P=0.006). On the second day, the mean frequency of watery diarrhea was 1.9 in the L. leuteri group and 3.4 in the placebo(P=0.046). Also, vomiting continued to the second day in 16 percent of patients receiving L. reuteri and 40 percent of those recieving placebo(P=0.031). Conclusion : L. reuteri is effective as a therapeutic agent in acute diarrhea in children.

목 적 : Lactobacilli의 일부 균주는 급성 설사의 회복을 도와 준다. Lactobacillus reuteri는 인간에서 비롯된 균주로 위장관 내에 자연적으로 집락형성을 한다. 특히 유아설사를 일으키는 로타바이러스를 억제하여 영유아 설사를 완화시켜주고 장내 다른 유익한 유산균 수를 증가시켜준다는 보고가 있다. 본 연구에서는 경구로 L. reuteri를 투여하였을 때 급성 설사에서 치료적 효과가 있는지 여부를 확인하고자 하였다. 방 법 : 급성 설사로 입원한 6개월에서 36개월 사이의 영유아 50명(40% 로타바이러스)을 대상으로 하였다. 환아들을 각 25명씩 무작위로 $10^8$ colony-forming unit(CFU)를 투여하는 L. reuteri군과 위약을 투여하는 위약군으로 나누어 하루에 2회 L. reuteri나 위약을 입원 기간 동안 혹은 최대한 5일간 투여하였다. 임상적인 평가로 입원 후 수양성 설사 기간, 입원 기간, 수양성 설사 일수 및 횟수, 구토 일수 등을 조사하였다. 결 과 : 설사 후 수양성 설사의 평균 기간은 L. reuteri군에서 2.3일이었으며 위약군에서 2.9일로 L. reuteri군에서 짧았으나 통계적 차이가 없었다(P=0.072). 치료 2병일째 수양성 설사는 L. reuteri군에서 64%이었으며 위약군에서 84%로 통계학적 차이가 있었다(P=0.006). 치료 2병일째 평균 수양성 설사횟수는 L. reuteri군에서 1.9회이었으며 위약군에서 3.4회로 통계학적 차이가 있었다(P=0.046). 치료 2병일째 구토는 L. reuteri군에서 16%이었으며 위약군에서 40%로 통계학적 차이가 있었다(P=0.031). 결 론 : 이상의 결과는 Lactobacillus reuteri가 영유아 설사에 치료효과가 있다는 것을 시사한다.

Keywords

References

  1. Jung JA. Etiology and management of acute diarrhea in children. Korean J Pediatr 2004:47 suppl 3:609-18
  2. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain(Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991;88:90-7
  3. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992;32:141-4 https://doi.org/10.1203/00006450-199208000-00002
  4. Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995;20:333-8 https://doi.org/10.1097/00005176-199504000-00012
  5. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997;24:399-404 https://doi.org/10.1097/00005176-199704000-00008
  6. Shornikova AV, Casas IA, Mykkanen H, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997;16:1103-7. https://doi.org/10.1097/00006454-199712000-00002
  7. Axelsson L, Chung TC, Dobrogosz WJ, Lindgren SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microbial Ecol Health Dis 1989;2:131-6 https://doi.org/10.3109/08910608909140210
  8. Casas IA, Edens FW, Dobrogosz WJ. Lactobacillus reuteri : an effective probiotic for poultry and other animals. In Salminen S, von Wright A. editiors. Lactic acid bacteria. 2nd ed. New York : Marcell Dekker Inc, 1998:457-518
  9. Talarico TL, Dobrogosz WJ. Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. Antimicrob Agents Chemother 1989;33:674-9 https://doi.org/10.1128/AAC.33.5.674
  10. Ragout A, Sineriz F, Diekmann H, de Valdez GF. Shifts in the fermentation balance of Lactobacillus reuteri in the presence of glycerol. Biotechnol Lett 1996;18:1105-8 https://doi.org/10.1007/BF00129740
  11. Talarico TL, Casas IA, Chung TC, Dobrogosz WJ. Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri. Antimicrob Agents Chemother 1988;32:1854-8 https://doi.org/10.1128/AAC.32.12.1854
  12. Chung TC, Axelsson L, Lindgren SE, Dobgrosz WJ. In vitro studies on reuterin synthesis by Lactobacillus reuteri. Microb Ecol Health Dis 1989;2:137-44 https://doi.org/10.3109/08910608909140211
  13. Fabia R, Ar'Rajab A, Johansson ML, Willen R, Andersson R, Molin G, et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acidinduced colitis in the rat. Scand J Gastroenterol 1993;28: 155-62. https://doi.org/10.3109/00365529309096063
  14. Mikelsaar M, Mandar R, Sepp E, Annuk H. Human lactic acid microflora and its role in the wellfare of the host. In : Salminen S, von Wright A, editors. Lactic acid bacteria. 3rd ed. New York. Marcel Dekker Inc, 2004:453-506
  15. Ray B. Fundamental food microbiology. 3rd ed. Oakdale : CRC Press, 2003:209-24
  16. Fuller R. Probiotics in human medicine. Gut 1991;32:439-42 https://doi.org/10.1136/gut.32.4.439
  17. Salminen S, Deighton M. Lactic acid bacteria in the gut in normal and disordered states. Dig Dis 1992;10:227-38 https://doi.org/10.1159/000171361
  18. Tazume S, Ozawa A, Yamamoto T, Takahashi Y, Takeshi K, Saidi SM, et al. Ecological study on the intestinal bacteria flora of patients with diarrhea. Clin Infect Dis 1993;16 suppl 2:77-82 https://doi.org/10.1093/clinids/16.Supplement_2.S77
  19. Salminen S, Isolauri E, Onnela T. Gut flora in normal and disordered states. Chemotherapy 1995;41 suppl 1:5-15
  20. Klein G, Pack A, Bonaparte C, Reuter G. Taxonomy and physiology of probiotic lactic acid bacteria. Int J Food Microbiol 1998;41:103-25 https://doi.org/10.1016/S0168-1605(98)00049-X
  21. Ruiz-Palacios G, Lourdes-Guerrero M, Hilty M, Dohnalek M, Newton P Calva T, et al. feeding of a probiotic for prevention of community acuired diarrha in young Mexican children. Ped Res 1996;39:1894
  22. Bass DM. Rotavirus and other agents of viral gastroenteritis. In : Behrman RE, Kliegman RM, Jenson HB, editors. Nelson textbook of pediatrics. 17th ed. Philadelphia : Saunders Co. 2004:1081-3
  23. Ma SH. Diagnosis and managements of viral gastroenteritis in children. J Korean Pediatr Soc 2003:46 suppl 1:133-52